Stable protein solution formulation containing high concentration of an anti-VEGF antibody
US-10689438-B2 · Jun 23, 2020 · US
Methods for treating ocular diseases with brolucizumab
US11098110B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11098110-B2 |
| Application number | US-201816018244-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 26, 2018 |
| Priority date | Nov 7, 2014 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating neovascular age-related macular degeneration (nAMD) in a patient, the method comprising administering to the patient three individual doses of a VEGF antagonist at 4-week intervals, and thereafter administering to the patient an additional dose every 12 weeks and monitoring the patient's best-corrected visual acuity (BCVA) for a decrease of letters due to nAMD disease activity to determine if the patient should receive a dose more frequently than once every 12 weeks, wherein each dose of the VEGF antagonist is at least 3 mg and the VEGF antagonist is brolucizumab. 2. The method of claim 1 , wherein each dose of the VEGF antagonist is 3 mg. 3. The method of claim 2 , wherein each dose of the VEGF antagonist is administered as a 50 μL intravitreal injection. 4. The method of claim 1 , wherein each dose of the VEGF antagonist is 6 mg. 5. The method of claim 4 , wherein each dose of the VEGF antagonist is administered as a 50 μL intravitreal injection. 6. The method of claim 1 , wherein a 12 week treatment interval is switched to an 8 week treatment interval if the patient's BCVA decreases ≥5 letters due to nAMD disease activity.
Assignees
Inventors
Classifications
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Single chain antibody (scFv) · CPC title
CH1 domain · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
- C07K16/22Primary
against growth factors {; against growth regulators} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11098110B2 cover?
- A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).